Lonza bone marrow and cord blood mononuclear cells

Monday, 18 April, 2011 | Supplied by: Capsugel Australia Pty Ltd

Lonza’s bone marrow and cord blood mononuclear cells are prepared by centrifugation in a density cell separation medium (Ficoll-Paque, Amersham Pharmacia).

Isolating the mononuclear cells eliminates erythrocytes and granulocytes, producing a more stable cell product.

Mononuclear cells can be used directly in hematopoietic assays or as the starting material for isolating CD34+ progenitor cells.

Cells are available cryopreserved with varying numbers or cells per ampule, starting from >25 million cells.

Online: lonzabioscience.com.au
Phone: 1300 657508

Content from other channels on our network

Outdated, overused and ineffective — time to end mandatory double-checking?

New Support at Home consumer protection measures announced

Chemical-free cleaning: the future of infection control in health care

Latrobe Regional Health charged after nurse "seriously assaulted" by patient

Charges laid following patient death at The Royal Melbourne Hospital

Submissions open for 2026 Melbourne Royal Food Awards

Swisslog to deliver a second frozen high bay warehouse project for Magnavale

Rockwell Automation releases 2026 State of Smart Manufacturing Report

IFPA A-NZ strengthens board with industry appointments

Weathering the storm: climate resilience in the food & beverage sector

AMCRC announces additive manufacturing research investment

PsiQuantum announces Australian site at Moreton Bay Central

Steelmaker reaches majority renewable electricity

Rockwell Automation releases 2026 State of Smart Manufacturing Report

ARM Hub announces Propel-AIR tour

Lonza bone marrow and cord blood mononuclear cells

LumiMount Fluorescence Mounting Medium

Innovative Research Animal Biologicals

EpigenTek EpiQuik CUT&RUN m6A RNA Enrichment (MeRIP) Kit

Content from other channels on our network